Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page

Mechanochemical ablation shows 96% closure rate at two years

Friday, 08 Jun 2012 14:29
Steve Elias
Steve Elias

At two years, mechanochemical ablation (MOCA) is as efficacious as current endothermal techniques without the need of tumescent anaesthesia and is more effective than reported results of foam sclerotherapy of the great saphenous vein. Steve Elias, who presented the first-in-man two-year results with the technique at the Vascular Annual Meeting (Washington DC, USA,7–9 June 2012), said that MOCA is another alternative modality for most incompetent great and small saphenous veins.

Elias, director, Division of Vascular Surgery Vein Programs, Columbia University and Medical Center, New York, USA, told delegates that the mechanochemical ablation catheter (ClariVein, Vascular Insights) utilises a liquid sclerosant (sodium tetradecyl sulfate or aethoxysclerol) and a mechanical rotating wire to accomplish occlusion of incompetent great or small saphenous vein. The procedure does not require tumescence and is performed with local anaesthesia at the access site only. It can be characterised as mechanically enhanced sclerotherapy performed in an office setting.

Thirty great saphenous veins in 29 patients underwent micropuncture access with local anaesthesia only in this first-in-man study. Through a 5F micropuncture sheath the MOCA catheter was passed to a position 2cm from the saphenofemoral junction. Catheter wire rotation was begun for 3 seconds at 3,500rpm. With the wire rotating, infusion of sclerosant (1.5% sodium tetradecyl sulfate) and catheter pullback (1.5mm/sec) was begun simultaneously. A total of 12cc of sclerosant was used for each great saphenous vein. The procedure does not require the instillation of tumescent aneasthesia.

At one year, 29 of 30 great saphenous veins were successfully treated. Primary closure rate 96%. At two years, 24 patients were examined. All 24 remain closed. No deep vein thrombosis, nerve or skin injury occurred. Average total procedure time was 14 minutes. Catheter treatment time was five minutes. The MOCA technique has been modified; lower volumes are now used based on diameter and length of vein treated. Catheter placement is closer to saphenofemoral junction (1cm).

Elias said that 6,000 cases have been treated with MOCA worldwide, with >90% occlusion rate. Quality of life was improved as with any successful endovenous ablation intervention. Deep vein thrombosis rate was below 1% and there was no nerve/skin injury. Elias also told delegates what we have learned about the technique: “Rotate first (spasm/vortex) then inject slow. Catheter on is catheter moving. It is a two-handed technique, one pulls and one injects.

The tendency is to pull too fast and to inject too slow.” About volume, he said, that it originally was 12cc (1.5% STD) for all. Now, he added, volume is based on diameter/length and tends to be less. On concentration, he said that stronger is better.

Elias summarised his presentation saying that MOCA works and is safe, with a learning curve of five to eight cases. It does not involve the use of tumescence anaesthesia and is another good option for ablation.

Add New Comment

Related Items

Most popular

Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions